Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | POLB | P06746 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593649 | 0.84 | THRB (0.66) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL1022265 | 0.82 | THRB (0.64) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL31258323 | 0.81 | THRB (0.68) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL20364679 | 0.81 | THRB (0.63) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL14587281 | 0.81 | THRB (1.00) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL18184682 | 0.81 | ALDH1A1 (0.63) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL22111001 | 0.80 | THRB (0.61) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL16859109 | 0.78 | THRB (0.59) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL7463215 | 0.78 | MAPT (0.72) | MAPTPOLBTP53SMN1; SMN2NPC1 | |
| SCHEMBL7468373 | 0.71 | MLLT1 (0.61) | MAPTPOLBTP53SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| EP-3002283-A1 | THIAZOLE DERIVATIVES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-1700856-B1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | DHFR, PRMT1, PRMT7 | MAPT 2806/4885POLB 279/4885TP53 4732/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | MAPT 4006/4885POLB 4509/4885TP53 2279/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | MAPT 476/4885POLB 3037/4885TP53 2637/4885 |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | HCRTR1, MTNR1A, HCRTR2 | MAPT 2204/4885POLB 3885/4885TP53 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.